secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000882095-23-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q3 2023: EPS beats on lower tax; raises full-year product sales guidance
-------------------------------------------------------------------------------

- Total revenue $7.1B flat YoY; product sales ex-Veklury up 5% to $6.4B.
- GAAP diluted EPS $1.73 vs $1.42 YoY; non-GAAP diluted EPS $2.29 vs $1.90.
- Biktarvy sales grew 12% to $3.1B; Oncology sales up 33% to $769M.
- Full-year product sales guidance raised to $26.7-26.9B; non-GAAP EPS raised to $6.65-6.85.
- Veklury sales fell 31% to $636M; R&D expenses rose to $1.5B on clinical activity and magrolimab discontinuations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209523000029/0000882095-23-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209523000029/gild-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000882095-23-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer